Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Clingan

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Oncology|June 20, 2022
A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED)Thiru Prasanna, Laeeq Malik, Robert D McCuaig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2021
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III StudySuresh S Ramalingam, Silvia Novello, Salih Zeki Guclu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancerJoachim von Pawel, Robert Jotte, David R Spigel, et al.
Lancet (London, England)|February 14, 2021
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trialAhmet Sezer, Saadettin Kilickap, Mahmut Gümüş, et al.
Journal for Immunotherapy of Cancer|October 17, 2023
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinomaPhilip Clingan, Rahul Ladwa, Daniel Brungs, et al.
Journal of the American Academy of Dermatology|October 7, 2025
Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 yearsEmily S Ruiz, Eva Muñoz-Couselo, Henri Montaudié, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2020
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung CancerShirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, et al.
The New England Journal of Medicine|April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerLeena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.
Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Oncology|June 20, 2022
A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED)Thiru Prasanna, Laeeq Malik, Robert D McCuaig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2021
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III StudySuresh S Ramalingam, Silvia Novello, Salih Zeki Guclu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancerJoachim von Pawel, Robert Jotte, David R Spigel, et al.
Lancet (London, England)|February 14, 2021
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trialAhmet Sezer, Saadettin Kilickap, Mahmut Gümüş, et al.
Journal for Immunotherapy of Cancer|October 17, 2023
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinomaPhilip Clingan, Rahul Ladwa, Daniel Brungs, et al.
Journal of the American Academy of Dermatology|October 7, 2025
Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 yearsEmily S Ruiz, Eva Muñoz-Couselo, Henri Montaudié, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2020
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung CancerShirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, et al.
The New England Journal of Medicine|April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerLeena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.
Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.
Pageof 2